SOURCE: Century Capital Markets

March 12, 2012 11:23 ET

WaferGen (WGBS) Names Former Johnson & Johnson (NYSE: JNJ) Manager to CEO Position

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the CENTURY CAPITAL MARKETS

NEW YORK, NY--(Marketwire - Mar 12, 2012) - WaferGen Biosystems, Inc. (OTCBB: WGBS), an emerging genomic analysis company in the early stage of commercialization, has announced today the appointment of Ivan Trifunovich, Ph.D., as President, CEO, and Director of the company. Dr. Trifunovich has held leadership positions at Third Wave Technologies (Now a part of Hologic (NASDAQ: HOLX)), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers (NYSE: BMY).

In a Daily Finance article on Genomic Research, WaferGen is highlighted as a possible buyout target. The article states, "One company that is a possible buyout target among the DNA-sequencing biotech group is WaferGen Biosystems, a leading developer and maker of systems for genomic analysis. Its chief product now on the market is SmartChip technology, which is used for analyzing gene expression. This is ideal for researchers seeking to confirm discoveries from the growing use of next-generation sequencing and to discover and validate biomarkers or gene expression patterns on a single platform."

The article quotes Raghuram Selvaraju, a biotech analyst at Hapoalim Securities, "With gene expression analysis now a focus in disease research and drug development, WaferGen could see significant growth in the sale of its SmartChip product over the coming years." Rating the stock a buy, he notes that with SmartChip's broad applicability, WaferGen "represents an attractive acquisition target for a number of established companies."

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid Century Capital Markets twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information